Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.64 |
| ▸ | QPCT | Q16769 | 5/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL14655620 | 0.80 | SMN1; SMN2 (0.48) | PDPK1QPCTRAB9AQPCTLPARP1 | |
| 2-Phenylthiazole SCHEMBL70646 | 0.80 | PDPK1 (1.00) | PDPK1CYP2A6RAB9ALOXL2METAP1 | |
| Benzimidazole SCHEMBL28095510 | 0.80 | ALDH1A1 (0.50) | PDPK1QPCTRAB9AQPCTLPARP1 | |
| SCHEMBL14720160 | 0.79 | QPCT (0.48) | PDPK1QPCTCYP2A6LOXL2QPCTL | |
| 2-Phenylthiazole SCHEMBL10519953 | 0.78 | PDPK1 (0.95) | PDPK1CYP2A6RAB9ALOXL2METAP1 | |
| 2-Phenylthiazole SCHEMBL4939218 | 0.78 | PDPK1 (0.95) | PDPK1CYP2A6RAB9ALOXL2METAP1 | |
| 2-Phenylthiazole SCHEMBL10667585 | 0.78 | PDPK1 (0.95) | PDPK1CYP2A6RAB9ALOXL2METAP1 | |
| 2-Phenylthiazole SCHEMBL28319382 | 0.78 | PDPK1 (0.95) | PDPK1CYP2A6RAB9ALOXL2METAP1 | |
| 2-Phenylthiazole SCHEMBL27882225 | 0.78 | PDPK1 (0.95) | PDPK1CYP2A6RAB9ALOXL2METAP1 | |
| Benzimidazole SCHEMBL1347288 | 0.78 | KDM4E (0.50) | PDPK1QPCTRAB9AQPCTLPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054874-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101032-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | PDPK1 2409/4885QPCT 506/4885CYP2A6 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.